189 related articles for article (PubMed ID: 26913850)
1. Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010).
Bona K; Blonquist TM; Neuberg DS; Silverman LB; Wolfe J
Pediatr Blood Cancer; 2016 Jun; 63(6):1012-8. PubMed ID: 26913850
[TBL] [Abstract][Full Text] [Related]
2. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
3. Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01.
Jiménez-Hernández E; Jaimes-Reyes EZ; Arellano-Galindo J; García-Jiménez X; Tiznado-García HM; Dueñas-González MT; Martínez Villegas O; Sánchez-Jara B; Bekker-Méndez VC; Ortíz-Torres MG; Ortíz-Fernández A; Marín-Palomares T; Mejía-Aranguré JM
Biomed Res Int; 2015; 2015():576950. PubMed ID: 25922837
[TBL] [Abstract][Full Text] [Related]
4. [Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].
SHAQ Multicenter Study Group of Children's Acute Lymphoblastic Leukemia Research
Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):495-501. PubMed ID: 24267129
[TBL] [Abstract][Full Text] [Related]
5. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
[TBL] [Abstract][Full Text] [Related]
7. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
[TBL] [Abstract][Full Text] [Related]
8. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
[TBL] [Abstract][Full Text] [Related]
9. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
Goldberg JM; Silverman LB; Levy DE; Dalton VK; Gelber RD; Lehmann L; Cohen HJ; Sallan SE; Asselin BL
J Clin Oncol; 2003 Oct; 21(19):3616-22. PubMed ID: 14512392
[TBL] [Abstract][Full Text] [Related]
10. Low socioeconomic status is a strong independent predictor of relapse in childhood acute lymphoblastic leukemia.
Viana MB; Fernandes RA; de Carvalho RI; Murao M
Int J Cancer Suppl; 1998; 11():56-61. PubMed ID: 9876480
[TBL] [Abstract][Full Text] [Related]
11. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.
Kahn JM; Cole PD; Blonquist TM; Stevenson K; Jin Z; Barrera S; Davila R; Roberts E; Neuberg DS; Athale UH; Clavell LA; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Sallan SE; Silverman LB; Kelly KM
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090520
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Nagatoshi Y; Inada H; Nakayama H; Yanai F; Ayukawa H; Kawakami K; Moritake H; Suminoe A; Okamura J
Pediatr Blood Cancer; 2005 Aug; 45(2):111-20. PubMed ID: 15782402
[TBL] [Abstract][Full Text] [Related]
13. Socioeconomic status and event free survival in pediatric acute lymphoblastic leukemia: a population-based cohort study.
Gupta S; Sutradhar R; Guttmann A; Sung L; Pole JD
Leuk Res; 2014 Dec; 38(12):1407-12. PubMed ID: 25224660
[TBL] [Abstract][Full Text] [Related]
14. Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience.
Navarrete M; Rossi E; Brivio E; Carrillo JM; Bonilla M; Vasquez R; Peña A; Fu L; Martinez R; Espinoza CM; Lacayo LF; Rodriguez H; Batista R; Barr R; Howard SC; Ribeiro RC; Masera G; Biondi A; Conter V; Valsecchi MG
Pediatr Blood Cancer; 2014 May; 61(5):803-9. PubMed ID: 24376115
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience.
Elashtokhy HEA; Elgohary HE; Eldeep BB; Gaber SM; Elbedewy TA
J Egypt Natl Canc Inst; 2021 Apr; 33(1):9. PubMed ID: 33826046
[TBL] [Abstract][Full Text] [Related]
16. Relapse-free rate with childhood acute lymphoblastic leukemia treated under the thai national protocol.
Tharnprisan P; Khiewyoo J; Sripraya P; Wiangnon S
Asian Pac J Cancer Prev; 2013; 14(2):1127-30. PubMed ID: 23621199
[TBL] [Abstract][Full Text] [Related]
17. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
18. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America.
Jaime-Pérez JC; Jiménez-Castillo RA; Pinzón-Uresti MA; Cantú-Rodríguez OG; Herrera-Garza JL; Marfil-Rivera LJ; Gómez-Almaguer D
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27957789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
